Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2017 05/18/2017 05/19/2017 05/22/2017 05/23/2017 Date
116.15(c) 116.67(c) 113.84(c) 115.42(c) 104.64(c) Last
1 414 210 2 014 148 2 613 737 2 228 059 18 836 943 Volume
-3.45% +0.45% -2.43% +1.39% -9.34% Change
More quotes
Financials ($)
Sales 2017 3 479 M
EBIT 2017 1 451 M
Net income 2017 721 M
Debt 2017 1 244 M
Yield 2017 -
Sales 2018 4 030 M
EBIT 2018 1 815 M
Net income 2018 1 081 M
Debt 2018 397 M
Yield 2018 -
P/E ratio 2017 32,43
P/E ratio 2018 21,36
EV / Sales2017 7,11x
EV / Sales2018 5,93x
Capitalization 23 498 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS, I
05/23 Nokia and Agilent rise; Alexion, Kirkland's fall
05/23 ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
05/23 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmac..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- 2nd Updat..
05/23 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Phar..
05/23DJALEXION PHARMACEUTICALS : Shakeup Continues as Four Executives Exit -- Update
05/23DJALEXION PHARMACEUTICALS : Management Shakeup Continues as Four More Executives E..
05/23 ALEXION PHARMACEUTICALS : Announces Executive Leadership Changes
05/18 ALEXION PHARMACEUTICALS : Global Headquarters Earns Highest LEED® Green Building..
05/18 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Alexion Pharm..
More news
Sector news : Biopharmaceuticals
12:20p FTSE edge up helped by M&S but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/23DJASTRAZENECA : Says Bydureon Trial Meets Safety Objectives; No Significant CV Red..
More sector news : Biopharmaceuticals
Latest Tweets
03:09pPharmalot.. Pharmalittle.. Good Morning.. Alexion shakes up mgmt & more n.. 
03:05p.@BW cover story on the lengths Alexion went to in selling its pricey orphan ..
1
02:51pThis on Alexion/orphan drugs from @ben_elgin @DoniBloomfield and @CarolineYL.. 
02:17p$ALXN (+0.5% pre) When the Patient Is a Gold Mine: The Trouble With Rare-Dise..
1
02:07pYikes. Sales people making medical calls? Alexion behavior threatens an impor..
28
More tweets
Qtime:179
News from SeekingAlpha
05/23 Leerink's Porges continues to see "significant value" in Alexion despite mana..
05/23 Midday Gainers / Losers
05/23 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
05/23 Alexion management turnover prompts a downgrade from JPM, $160 PT unchanged
05/23 Executives transition at Alexion as new chief Hantson settles in
Advertisement
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 160 $
Spread / Average Target 53%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
David John Anderson Chief Financial Officer & Executive Vice President
Martin MacKay Executive VP, Global Head-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICAL..-14.47%25 918
BIOGEN INC-5.06%53 037
CSL LIMITED29.74%44 135
GRIFOLS SA33.77%17 672
BIOMARIN PHARMACEUTICA..6.66%15 790
CHONGQING ZHIFEI BIOLO..--.--%4 422
More Results